Echinocandin activity against Aspergillus spp. and the importance of pharmacodynamics

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Lewis II, James S ^a,b  

^a UNIVERSITY HEALTH SYSTEM   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Aspergillus; Echinocandins; Pharmacodynamics

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; ANTIFUNGAL AGENT;

AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; IN VITRO STUDY; INVASIVE ASPERGILLOSIS; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; ANIMAL; DRUG COMBINATION; DRUG EFFECT; HUMAN; LUNG ASPERGILLOSIS; MICROBIAL VIABILITY; MICROBIOLOGY; REVIEW;

ANIMALIA; ASPERGILLUS;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MICROBIAL VIABILITY;

EID: 67651123296     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802603698     Document Type: Article

References (31)

1. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diag Microbiol Infect Dis 1998; 30: 251-255.
2. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369-388.
3. Vazquez JA, Sobel JD. Anidulafungin: A novel echinocandin. Clin Infect Dis 2006; 43: 215-222.
4. Meyer V, Damveld RA, Arentshorst M, et al. Survival in the presence of antifungals: Genome-wide expression profiling of Aspergillus niger in response to sublethal concentrations of caspofungin and fenpropimorph. J Biol Chem 2007; 282: 32935-32948.
5. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-3012.
6. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Micro 1998; 36: 2950-2956.
7. Paderu P, Garcia-Effron G, Balashov S, et al. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51: 2253-2256.
8. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-1489.
9. Merck & Co. Cancidas (caspofungin) package insert. Whitehouse Station, NJ; 2008.
10. Astellas Pharma US. Mycamine (micafungin) package insert. Deerfield, IL; 2005.
11. Pfizer Inc. Eraxis (anidulafungin) package insert. New York, NY; 2006.
12. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151.
13. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45 2845-2855.
14. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898-2905.
15. Warn PA, Morrissey G, Morrissey J, Denning DW. Activity of micafungin (FK463) against an intraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51: 913-919.
16. Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-1471.
17. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-1869.
18. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12-23.
19. van Vianen W, de Marie S, ten Kate MT, et al. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57: 732-740.
20. Andes D, Marchillo K, Lowther J, et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1187-1192.
21. Andes D, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 539-550.
22. Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-5068.
23. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
24. Kartsonis NA, Saah AJ, Lipka CJ, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: Results from the caspofungin compassionate use study. J Infect 2005; 50: 196-205.
25. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-349.
26. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
27. Buell D, Kovanda L, Drake T, Frisco C. Alternative day dosing of micafungin for esophageal candidiasis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16-19 December 2005. American Society for Microbiology 2005: Abstract M-719.
28. Safdar A, Rodriguez G, Rolston KVI, et al. High dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 157-164.
29. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-2897.
30. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297.
31. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008; 46: 327-360.